A Study to Investigate the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Participants With Autism Spectrum Disorder
Status: | Recruiting |
---|---|
Conditions: | Neurology, Psychiatric, Psychiatric, Autism |
Therapuetic Areas: | Neurology, Psychiatry / Psychology |
Healthy: | No |
Age Range: | 13 - 30 |
Updated: | 2/13/2019 |
Start Date: | November 7, 2018 |
End Date: | March 3, 2021 |
Contact: | Study Contact |
Email: | JNJ.CT@sylogent.com |
Phone: | 844-434-4210 |
A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Investigating the Efficacy, Safety, and Tolerability of JNJ-42165279 in Adolescent and Adult Subjects With Autism Spectrum Disorder
The purpose of this study is to evaluate the efficacy of JNJ-42165279 compared with placebo
in the improvement of symptoms of Autism Spectrum Disorder (ASD) during 12 weeks of treatment
using the Autism Behavior Inventory (ABI).
in the improvement of symptoms of Autism Spectrum Disorder (ASD) during 12 weeks of treatment
using the Autism Behavior Inventory (ABI).
Inclusion Criteria:
- Diagnosis of Autism Spectrum Disorder (ASD) according to Diagnostic and Statistical
Manual of Mental Disorders - 5th Edition (DSM-5) criteria and made or confirmed using
the Autism Diagnostic Observation Schedule, 2nd edition (ADOS-2) (minimum score of 8
[autism spectrum])
- Otherwise healthy for their age group or medically stable with or without medication
on the basis of physical examination, medical history, vital signs, 12-lead
electrocardiogram (ECG), and clinical laboratory tests
- Have a composite score on Kaufman Brief Intelligence Test, Second Edition (KBIT-2) of
at least 60
- Must live with a parent or primary caregiver or, if not, during each week he/she must
either (A) spend at least 3 hours a day for at least 4 days or, (B) spend the weekend
with a parent or primary caregiver
- Any pharmacologic, diet, or behavioral intervention for ASD must have begun at least 1
month prior to the baseline visit and continue unchanged through the treatment period,
or have ended at least 1 month prior to the baseline visit
- Must be able to swallow the study medication whole and self-administer medication if
living independently or have a parent or caregiver be able to administer medication
- Must agree to abide by the birth control requirements during the study and for 3
months after the last dose
Exclusion Criteria:
- Current or recent history of clinically significant suicidal ideation within the past
6 months, or a history of suicidal behavior within the past year
- Use of a drug with moderate/strong cytochrome P450 (CYP)3A4 inhibiting or inducing
properties at, or prior to, screening that is not discontinued at least within 1 month
prior to Day 1
- History of drug or alcohol use disorder according to DSM-5 criteria within 6 months
before screening or positive test result(s) for alcohol or drugs of abuse (except if
related to current treatment)
- Currently taking or has taken within the past month recreational or medically
prescribed cannabis
We found this trial at
3
sites
Seattle Children's Hospital Seattle Children’s Hospital specializes in meeting the unique physical, emotional and developmental...
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials